Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
Author:
Affiliation:
1. Jewish General HospitalMontréal, Canada
2. McGill UniversityMontréal, Canada
3. Brigham and Women’s HospitalBoston, Massachusetts
4. Harvard Medical SchoolBoston, Massachusetts
Publisher
American Thoracic Society
Subject
Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine
Link
https://www.atsjournals.org/doi/pdf/10.1164/rccm.202207-1301LE
Reference30 articles.
1. Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions
2. Drug Treatment of Idiopathic Pulmonary Fibrosis
3. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
4. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
5. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Decoding Molecular Heterogeneity in Idiopathic Pulmonary Fibrosis;American Journal of Respiratory and Critical Care Medicine;2024-08-15
2. Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era;European Respiratory Journal;2024-08
3. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias;Respiratory Research;2024-07-31
4. Inhibition of TGF-β1/Smad3 signaling by compound 5aa: A potential treatment for idiopathic pulmonary fibrosis;Bioorganic Chemistry;2024-06
5. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision;Respirology;2024-01-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3